PF-05280586 vs Rituximab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
PF-05280586
Marketed by Pfizer
NCT01526057 · Phase 2 · completed
The 220-participant trial was randomized, quadruple-blind, and actively controlled with European- and US-sourced rituximab. The primary pharmacokinetic comparisons met the prespecified equivalence range for both peak concentration and total drug exposure, but these were surrogate measures rather than hard clinical outcomes, supporting a moderate evidence grade.
Reported efficacy
Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion); AUC 0-inf of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Maximum Serum Concentration (Cmax) of Rituximab (Predose (Day 1) and 3, 4.25 (immediately before 1st infusion end), 72, 168, 335 (Day 15 within 1.5 hours before 2nd infusion), 337.5, 339.25 (Day 15 immediately before 2nd infusion end), 408, 504, 672, 1344, and 2016 hours after start of 1st infusion): Rituximab-Pfizer 453 micrograms per milliliter (Standard Deviation 153) | Rituximab-EU 422 micrograms per milliliter (Standard Deviation 111) | Rituximab-US 430 micrograms per milliliter (Standard Deviation 163) (met)
Result source: NCT01526057
Rituximab · Rituxan
Marketed by Roche and partners
NCT00468546 · Phase 3 · completed
The REFLEX phase 3 trial: randomized, double-blind, placebo-controlled, 520 participants with rheumatoid arthritis who had failed anti-TNF therapy, all on background methotrexate. The primary endpoint, ACR20 response at week 24, was reached by 153 of 298 participants on rituximab (51.3%) versus 36 of 201 on placebo (17.9%). ClinicalTrials.gov records no statistical analysis for the comparison, but a 33-percentage-point difference on a validated clinical response endpoint at this sample size is arithmetically undeniable, so the primary is read as met (significance inferred from counts).
Next expected readout: July 2027 · NCT06581562 (registry estimate)
Reported efficacy
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3% (met)
Result source: NCT00299130
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | PF-05280586 | Rituximab |
|---|---|---|
| ACR20 | 77.1% vs 90%vs Rituximab-EUNCT0164392818 other results
| 50.6% vs 23.3%+27.3 vs placeboNCT002991305 other results
|
| ACR50 | 51.4% vs 30%vs Rituximab-EUNCT0164392818 other results
| 64.8% vs 41.8%+23 vs placeboNCT002991046 other results
|
| ACR70 | 22.9% vs 10%vs Rituximab-EUNCT0164392818 other results
| 46.8% vs 24.9%+21.9 vs placeboNCT002991046 other results
|
| DAS28-CRP remission | 45.7% vs 20%vs Rituximab-EUNCT0164392811 other results
| —Not posted · NCT00578305 |
| HAQ-DI, change | -0.4 vs -0.5vs RituximabNCT015260576 other results
| -1.1 vs -0.8−0.2 vs placeboNCT002991049 other results
|
| Modified Sharp score, change | —Not reported | 0.4 vs 1.1−0.7 vs placeboNCT002991046 other results
|
ACR20
- PF-05280586
- 77.1% vs 90%vs Rituximab-EUNCT01643928
18 other results
- 81.8% vs 90% NCT01643928
- 73.7% vs 90% NCT01643928
- 69.6% vs 77.4% NCT01643928
- 84.8% vs 77.4% NCT01643928
- 82.8% vs 77.4% NCT01643928
- 66.7% vs 71% NCT01643928
- 84.8% vs 71% NCT01643928
- 76.7% vs 71% NCT01643928
- 50% vs 59.4% NCT01643928
- 63.6% vs 59.4% NCT01643928
- 60% vs 59.4% NCT01643928
- 50% vs 60.3% NCT01526057
- 54.2% vs 62.2% NCT01526057
- 54.8% vs 67.6% NCT01526057
- 50.7% vs 70.3% NCT01526057
- 49.3% vs 60.8% NCT01526057
- 54.8% vs 56.8% NCT01526057
- 34.2% vs 33.8% NCT01526057
- Rituximab
- 50.6% vs 23.3%+27.3 vs placeboNCT00299130
5 other results
- 54.5% vs 23.3% NCT00299130
- 53.5% vs 44.6% NCT00266227
- 51.3% vs 17.9% NCT00468546
- 80% vs 64.3% NCT00299104
- 76.7% vs 64.3% NCT00299104
ACR50
- PF-05280586
- 51.4% vs 30%vs Rituximab-EUNCT01643928
18 other results
- 63.6% vs 30% NCT01643928
- 36.8% vs 30% NCT01643928
- 37.5% vs 41.9% NCT01643928
- 66.7% vs 41.9% NCT01643928
- 58.6% vs 41.9% NCT01643928
- 33.3% vs 51.6% NCT01643928
- 51.5% vs 51.6% NCT01643928
- 53.3% vs 51.6% NCT01643928
- 17.2% vs 28.1% NCT01643928
- 48.5% vs 28.1% NCT01643928
- 30% vs 28.1% NCT01643928
- 21% vs 38.1% NCT01526057
- 27.8% vs 37.8% NCT01526057
- 24.7% vs 36.5% NCT01526057
- 35.6% vs 40.5% NCT01526057
- 21.9% vs 32.4% NCT01526057
- 19.2% vs 16.2% NCT01526057
- 8.2% vs 5.4% NCT01526057
- Rituximab
- 64.8% vs 41.8%+23 vs placeboNCT00299104
6 other results
- 34.1% vs 18.6% NCT00299130
- 25.9% vs 9.3% NCT00299130
- 59.4% vs 41.8% NCT00299104
- 32.9% vs 18.6% NCT00299130
- 26.3% vs 9.3% NCT00299130
- 26.8% vs 5.5% NCT00468546
ACR70
- PF-05280586
- 22.9% vs 10%vs Rituximab-EUNCT01643928
18 other results
- 36.4% vs 10% NCT01643928
- 15.8% vs 10% NCT01643928
- 23.2% vs 32.3% NCT01643928
- 36.4% vs 32.3% NCT01643928
- 34.5% vs 32.3% NCT01643928
- 21.1% vs 22.6% NCT01643928
- 33.3% vs 22.6% NCT01643928
- 30% vs 22.6% NCT01643928
- 5.2% vs 12.5% NCT01643928
- 21.2% vs 12.5% NCT01643928
- 10% vs 12.5% NCT01643928
- 16.1% vs 17.5% NCT01526057
- 13.9% vs 23% NCT01526057
- 15.1% vs 18.9% NCT01526057
- 19.2% vs 28.4% NCT01526057
- 12.3% vs 17.6% NCT01526057
- 6.8% vs 6.8% NCT01526057
- 2.7% vs 2.7% NCT01526057
- Rituximab
- 46.8% vs 24.9%+21.9 vs placeboNCT00299104
6 other results
- 13.5% vs 9.3% NCT00299130
- 10% vs 5.2% NCT00299130
- 42.2% vs 24.9% NCT00299104
- 12.6% vs 9.3% NCT00299130
- 9% vs 5.2% NCT00299130
- 12.4% vs 1.5% NCT00468546
DAS28-CRP remission
- PF-05280586
- 45.7% vs 20%vs Rituximab-EUNCT01643928
11 other results
- 27.3% vs 20% NCT01643928
- 21.1% vs 20% NCT01643928
- 33.9% vs 46.7% NCT01643928
- 45.5% vs 46.7% NCT01643928
- 37.9% vs 46.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 34.4% vs 38.7% NCT01643928
- 32.1% vs 38.7% NCT01643928
- 3.9% vs 10.7% NCT01643928
- 19.4% vs 10.7% NCT01643928
- 7.1% vs 10.7% NCT01643928
- Rituximab
- —Not posted · NCT00578305
HAQ-DI, change
- PF-05280586
- -0.4 vs -0.5vs RituximabNCT01526057
6 other results
- -0.4 vs -0.6 NCT01526057
- -0.3 vs -0.6 NCT01526057
- -0.4 vs -0.6 NCT01526057
- -0.4 vs -0.5 NCT01526057
- -0.3 vs -0.3 NCT01526057
- -0.2 vs -0.2 NCT01526057
- Rituximab
- -1.1 vs -0.8−0.2 vs placeboNCT00299104
9 other results
- -1.0 vs -0.8 NCT00299104
- -1038 vs -0.8 NCT00299104
- -1.0 vs -0.8 NCT00299104
- -0.3 vs -0.2 NCT00266227
- -0.4 vs -0.2 NCT00578305
- -0.4 vs -0.2 NCT00578305
- -0.5 vs -0.2 NCT00578305
- -0.4 vs -0.2 NCT00578305
- -0.5 vs -0.4 NCT02097745
Modified Sharp score, change
- PF-05280586
- —Not reported
- Rituximab
- 0.4 vs 1.1−0.7 vs placeboNCT00299104
6 other results
- 0.6 vs 1.1 NCT00299104
- 0.4 vs 1.9 NCT00299104
- 0.3 vs 0.7 NCT00299104
- 0.8 vs 1.9 NCT00299104
- 0.5 vs 0.7 NCT00299104
- 3.2 vs 5.4 NCT02097745
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
13 other shared endpoints and safety
Coverage. PF-05280586: 17 of 17 rows · Rituximab: 17 of 17 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | PF-05280586 Rows use multiple source trials | Rituximab Rows use multiple source trials |
|---|---|---|
| DAS Low Disease Activity responder rate · % of participants | 32% (n=73) vs 37.9% (n=74) Rituximab @ 25wka,b,c,d NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 | 43% (n=249) vs 19.8% (n=247) placebo @ 52wk1.0 g x 2e,a,b,c,d NCT00299104 · Phase 3 · combination show 1 more dose40.3% (n=248) vs 19.8% (n=247) placebo @ 52wk0.5 g x 2 NCT00299104 · Phase 3 · combination |
| DAS28-CRP absolute change · score | -1.7 vs -2 Rituximab score @ 25wka,b,c,f NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 | -1.8 vs -1.5 placebo score @ 48wka,b,c,f NCT00266227 · Phase 3 |
| EULAR Good responder rate · % of participants | 30% (n=73) vs 36.2% (n=74) Rituximab @ 25wka,b,c,d NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 3 other source trials36.4% (n=33) vs 20% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence 36.8% (n=30) vs 20% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence 57.1% (n=58) vs 20% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | 41.6% (n=250) vs 18.1% (n=249) placebo @ 52wk1.0 g x 2e,a,b,c,d NCT00299104 · Phase 3 · combination show 1 more dose39% (n=249) vs 18.1% (n=249) placebo @ 52wk0.5 g x 2 NCT00299104 · Phase 3 · combination |
| HAQ-DI percent change · % of baseline | -43.6% (n=33) vs -24.1% (n=32) Rituximab-EU @ 25wke,g,b,c,f NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-27.2% (n=30) vs -24.1% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -26.3% (n=58) vs -24.1% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -30.6% (n=170) vs -22.6% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f NCT00299130 · Phase 3 · combination show 1 more dose-30.2% (n=167) vs -22.6% (n=172) placebo @ 48wk2 x 0.5 g NCT00299130 · Phase 3 · combination |
| Patient Assessment of Arthritis Pain percent change · % of baseline | -52.5% (n=33) vs -19.6% (n=32) Rituximab-EU @ 25wke,g,b,c,f NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-45.4% (n=30) vs -19.6% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -49.7% (n=58) vs -19.6% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -36.3% (n=170) vs -24.4% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f NCT00299130 · Phase 3 · combination show 1 more dose-35.5% (n=167) vs -24.4% (n=172) placebo @ 48wk2 x 0.5 g NCT00299130 · Phase 3 · combination |
| Patient Global Assessment percent change · % of baseline | -48.4% (n=33) vs -42.3% (n=32) Rituximab-EU @ 25wke,g,b,c,f NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-46.5% (n=30) vs -42.3% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -52.6% (n=58) vs -42.3% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -36.6% (n=170) vs -28% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f NCT00299130 · Phase 3 · combination show 1 more dose-39.7% (n=167) vs -28% (n=172) placebo @ 48wk2 x 0.5 g NCT00299130 · Phase 3 · combination |
| Physician Global Assessment percent change · % of baseline | -71.4% (n=33) vs -73.2% (n=32) Rituximab-EU @ 25wke,g,b,c,f NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-59.9% (n=30) vs -73.2% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -67% (n=58) vs -73.2% (n=32) Rituximab-EU @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -49% (n=170) vs -39.4% (n=172) placebo @ 48wk2 x 1.0 ge,g,b,c,f NCT00299130 · Phase 3 · combination show 1 more dose-40.5% (n=167) vs -39.4% (n=172) placebo @ 48wk2 x 0.5 g NCT00299130 · Phase 3 · combination |
| SJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 13 | -77.8% (n=31) @ 13wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 5 more doses-77% (n=30) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence -70% (n=29) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence -70% (n=29) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence -78.3% (n=54) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence -79.3% (n=48) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence | -47.2% (n=32) @ 13wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-79.5% (n=30) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence |
| SJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 25 | -76% (n=31) @ 25wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 5 more doses-74.8% (n=30) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -67.2% (n=29) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -67.2% (n=29) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -75% (n=54) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -73.5% (n=48) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -74.1% (n=32) @ 25wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-58.6% (n=30) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence |
| SJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 6 | -72.5% (n=31) @ 6wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 5 more doses-71.5% (n=30) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence -78.2% (n=29) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence -78.2% (n=29) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence -62.7% (n=54) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence -62.1% (n=48) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence | -55.1% (n=32) @ 6wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-68.2% (n=30) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence |
| TJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 13 | -73.7% (n=30) @ 13wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-68.7% (n=29) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence -75.1% (n=48) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence | -76.6% (n=32) @ 13wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-70.6% (n=30) @ 13wk NCT01643928 · Phase na · registry result, not featured evidence |
| TJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 25 | -68.8% (n=30) @ 25wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-69.9% (n=29) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence -69% (n=48) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence | -57.1% (n=32) @ 25wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-57% (n=30) @ 25wk NCT01643928 · Phase na · registry result, not featured evidence |
| TJC percent change · % of baseline No placebo or comparator arm Change at Course 1/Week 6 | -73.3% (n=30) @ 6wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 2 more doses-70.5% (n=29) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence -53.6% (n=48) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence | -72.1% (n=32) @ 6wke,b,c NCT01643928 · Phase na · registry result, not featured evidence show 1 more dose-68.7% (n=30) @ 6wk NCT01643928 · Phase na · registry result, not featured evidence |
| Dropout rate | 12.3%h NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 17.2%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 9.1%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 17.9%i NCT00468546 · Phase 3 · combination show 48 more results— NCT00266227 · Phase 3 68.3%1.0 g x 2 NCT00299104 · Phase 3 · combination 69.4%0.5 g x 2 NCT00299104 · Phase 3 · combination —1.0 g NCT00299130 · Phase 3 · combination 29.2%2 x 1.0 g NCT00299130 · Phase 3 · combination 25.6%2 x 0.5 g NCT00299130 · Phase 3 · combination 20.8% NCT01382940 · Phase 4 · registry result, not featured evidence 33.3% NCT01000610 · Phase 4 · registry result, not featured evidence —1000 mg NCT00934648 · Phase 4 · registry result, not featured evidence — NCT00502853 · Phase 4 · registry result, not featured evidence · combination — NCT00504777 · Phase 4 · registry result, not featured evidence · combination —1000 mg NCT00424502 · Phase 4 · registry result, not featured evidence 7.5% NCT00462345 · Phase 4 · registry result, not featured evidence · combination 53.1% NCT02097745 · Phase 3 · registry result, not featured evidence 25.1% NCT00503425 · Phase 3 · registry result, not featured evidence 6.7%1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence 4.8%500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 12%Decreased Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 11.7%Escalated Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 4.3%High Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination —Low Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 23.7%1000 mg NCT00443651 · Phase 3 · registry result, not featured evidence 33%500 mg NCT00443651 · Phase 3 · registry result, not featured evidence 32.1%1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence —1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence 16.4%1000 mg x 2 NCT01126541 · Phase 3 · registry result, not featured evidence — NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy 30% NCT00578565 · Phase 3 · registry result, not featured evidence — NCT02079532 · Phase 3 · registry result, not featured evidence · combination —Initial Treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination —Re-treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination 19% NCT00502996 · Phase 3 · registry result, not featured evidence — NCT02006706 · Phase 3 · registry result, not featured evidence · combination 41.5% NCT02093026 · Phase 2 · registry result, not featured evidence 5.8%Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination —Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination 0% NCT00147966 · Phase 2 · registry result, not featured evidence 52.4%1000 mg NCT00243412 · Phase 2 · registry result, not featured evidence 47.6%500 mg NCT00243412 · Phase 2 · registry result, not featured evidence —Rituximab-EU: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —Rituximab-US: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 0% NCT00844714 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 4.1%h NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results—PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 0%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 2.6%i NCT00468546 · Phase 3 · combination show 48 more results— NCT00266227 · Phase 3 2.8%1.0 g x 2 NCT00299104 · Phase 3 · combination 3.6%0.5 g x 2 NCT00299104 · Phase 3 · combination —1.0 g NCT00299130 · Phase 3 · combination 7.6%2 x 1.0 g NCT00299130 · Phase 3 · combination 4.8%2 x 0.5 g NCT00299130 · Phase 3 · combination 5.4% NCT01382940 · Phase 4 · registry result, not featured evidence 5.6% NCT01000610 · Phase 4 · registry result, not featured evidence —1000 mg NCT00934648 · Phase 4 · registry result, not featured evidence — NCT00502853 · Phase 4 · registry result, not featured evidence · combination — NCT00504777 · Phase 4 · registry result, not featured evidence · combination —1000 mg NCT00424502 · Phase 4 · registry result, not featured evidence — NCT00462345 · Phase 4 · registry result, not featured evidence · combination 7.5% NCT02097745 · Phase 3 · registry result, not featured evidence 2.3% NCT00503425 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 0%Decreased Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 2.5%Escalated Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 1.1%High Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination —Low Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 1.2%1000 mg NCT00443651 · Phase 3 · registry result, not featured evidence 3.4%500 mg NCT00443651 · Phase 3 · registry result, not featured evidence 4.9%1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence —1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence 2.7%1000 mg x 2 NCT01126541 · Phase 3 · registry result, not featured evidence — NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy 30% NCT00578565 · Phase 3 · registry result, not featured evidence — NCT02079532 · Phase 3 · registry result, not featured evidence · combination —Initial Treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination —Re-treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination 0.9% NCT00502996 · Phase 3 · registry result, not featured evidence — NCT02006706 · Phase 3 · registry result, not featured evidence · combination 5.6% NCT02093026 · Phase 2 · registry result, not featured evidence 0%Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination —Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination — NCT00147966 · Phase 2 · registry result, not featured evidence 9.5%1000 mg NCT00243412 · Phase 2 · registry result, not featured evidence 19%500 mg NCT00243412 · Phase 2 · registry result, not featured evidence —Rituximab-EU: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence —Rituximab-US: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence — NCT00844714 · Phase na · registry result, not featured evidence |
| Serious AEs | 6.8%h NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 12 more results6.1%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 12.9%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 13.3%PF-05280586 (EU): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 6.7%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence 3.4%PF-05280586 (US): by the End of Co NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence —PF-05280586/PF-05280586/PF-0528058 NCT01643928 · Phase na · registry result, not featured evidence 6.9%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 11.1%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 8.3%PF-05280586: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence | 16.2%i NCT00468546 · Phase 3 · combination show 48 more results13.1% NCT00266227 · Phase 3 22.1%1.0 g x 2 NCT00299104 · Phase 3 · combination 15.5%0.5 g x 2 NCT00299104 · Phase 3 · combination 27.1%1.0 g NCT00299130 · Phase 3 · combination —2 x 1.0 g NCT00299130 · Phase 3 · combination 31.1%2 x 0.5 g NCT00299130 · Phase 3 · combination 8.5% NCT01382940 · Phase 4 · registry result, not featured evidence 33.3% NCT01000610 · Phase 4 · registry result, not featured evidence 0%1000 mg NCT00934648 · Phase 4 · registry result, not featured evidence 20% NCT00502853 · Phase 4 · registry result, not featured evidence · combination 8.3% NCT00504777 · Phase 4 · registry result, not featured evidence · combination 0%1000 mg NCT00424502 · Phase 4 · registry result, not featured evidence 15% NCT00462345 · Phase 4 · registry result, not featured evidence · combination 58.8% NCT02097745 · Phase 3 · registry result, not featured evidence 33.5% NCT00503425 · Phase 3 · registry result, not featured evidence —1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence 6.7%1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence 10.6%1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence 1.9%1000 mg NCT00578305 · Phase 3 · registry result, not featured evidence —500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 4.8%500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 6%500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 0%500 mg NCT00578305 · Phase 3 · registry result, not featured evidence 12%Decreased Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 17.6%Escalated Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 17.2%High Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 11.2%Low Dose NCT00422383 · Phase 3 · registry result, not featured evidence · combination 12%1000 mg NCT00443651 · Phase 3 · registry result, not featured evidence 15.3%500 mg NCT00443651 · Phase 3 · registry result, not featured evidence 19.8%1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence 28.8%1000 mg NCT01126541 · Phase 3 · registry result, not featured evidence 36.8%1000 mg x 2 NCT01126541 · Phase 3 · registry result, not featured evidence 24.4% NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy 20% NCT00578565 · Phase 3 · registry result, not featured evidence 11.9% NCT02079532 · Phase 3 · registry result, not featured evidence · combination 10%Initial Treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination 9.1%Re-treatment: Rituximab + MTX NCT01272908 · Phase 3 · registry result, not featured evidence · combination 5.2% NCT00502996 · Phase 3 · registry result, not featured evidence 14.3% NCT02006706 · Phase 3 · registry result, not featured evidence · combination 49.5% NCT02093026 · Phase 2 · registry result, not featured evidence —Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination 4.4%Rituximab + Methotrexate (Group A) NCT00282308 · Phase 2 · registry result, not featured evidence · combination 8.3% NCT00147966 · Phase 2 · registry result, not featured evidence 10%1000 mg NCT00243412 · Phase 2 · registry result, not featured evidence 14.3%500 mg NCT00243412 · Phase 2 · registry result, not featured evidence 6.3%Rituximab-EU: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 3.3%Rituximab-US: by the End of Course NCT01643928 · Phase na · registry result, not featured evidence 0% NCT00844714 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | h upper respiratory tract infection 9.6% fatigue 6.8% hypertension 5.5% NCT01526057 · Phase 2 · Rheumatoid Arthritis · phase 2 show 9 more resultsrheumatoid arthritis 9.1% vomiting 6.1% back pain 3% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.7% back pain 6.5% sinusitis 6.5% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 10% urinary tract infection 10% arthralgia 6.7% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.7% oropharyngeal pain 6.7% gastroenteritis 3.3% NCT01643928 · Phase na · registry result, not featured evidence diarrhoea 6.9% nausea 6.9% oropharyngeal pain 6.9% NCT01643928 · Phase na · registry result, not featured evidence upper respiratory tract infection 10.3% alanine aminotransferase increased 6.9% aspartate aminotransferase increased 6.9% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 6.9% urinary tract infection 6.9% fatigue 5.2% NCT01643928 · Phase na · registry result, not featured evidence rheumatoid arthritis 9.3% urinary tract infection 9.3% bronchitis 7.4% NCT01643928 · Phase na · registry result, not featured evidence bronchitis 10.4% rheumatoid arthritis 10.4% urinary tract infection 10.4% NCT01643928 · Phase na · registry result, not featured evidence | i rheumatoid arthritis 34.4% (placebo 41.8%) upper respiratory tract infection 11.7% (placebo 8.2%) headache 10.1% (placebo 10.1%) NCT00468546 · Phase 3 · combination show 42 more resultsrheumatoid arthritis 23.1% (placebo 38.1%) upper respiratory tract infection 22.2% (placebo 20.6%) headache 15.9% (placebo 11.6%) NCT00266227 · Phase 3 1.0 g x 2 infusion related reaction 25.5% (placebo 21.3%) upper respiratory tract infection 22.1% (placebo 17.7%) nasopharyngitis 19.8% (placebo 17.3%) NCT00299104 · Phase 3 · combination 0.5 g x 2 infusion related reaction 19.8% (placebo 21.3%) upper respiratory tract infection 17% (placebo 17.7%) nasopharyngitis 15.2% (placebo 17.3%) NCT00299104 · Phase 3 · combination 1.0 g infusion related reaction 34.7% (placebo 19.2%) upper respiratory tract infection 29.4% (placebo 7.6%) nasopharyngitis 24.7% (placebo 9.9%) NCT00299130 · Phase 3 · combination 2 x 0.5 g infusion related reaction 35.3% (placebo 19.2%) upper respiratory tract infection 35.3% (placebo 7.6%) rheumatoid arthritis 29.3% (placebo 17.4%) NCT00299130 · Phase 3 · combination headache 5.7% upper respiratory tract infection 5.4% NCT01382940 · Phase 4 · registry result, not featured evidence hypertension 11.1% blurred vision 5.6% dyspnea stage 2 5.6% NCT01000610 · Phase 4 · registry result, not featured evidence 1000 mg difficulty breathing 6.7% diffuse skin rash 6.7% dyspnea 6.7% NCT00934648 · Phase 4 · registry result, not featured evidence influenza 30% pharyngitis 30% alanine aminotransferase increased 20% NCT00502853 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 22.2% cough 13.9% dizziness 5.6% NCT00504777 · Phase 4 · registry result, not featured evidence · combination 1000 mg fever 10% throat pain 10% upper respiratory tract infection 10% NCT00424502 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 30% rash 15% arthralgia 12.5% NCT00462345 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 64.8% (placebo 40.7%) infusion related reaction 46.3% (placebo 18.6%) upper respiratory tract infection 39.4% (placebo 10%) NCT02097745 · Phase 3 · registry result, not featured evidence back pain 13.4% rheumatoid arthritis 12% vitamin d deficiency 10.5% NCT00503425 · Phase 3 · registry result, not featured evidence 1000 mg bronchitis 8.3% (placebo 3.2%) back pain 6.7% (placebo 1.6%) upper respiratory tract infection 6.7% (placebo 1.6%) NCT00578305 · Phase 3 · registry result, not featured evidence 1000 mg arthralgia 0% (placebo 1.6%) back pain 0% (placebo 1.6%) bronchitis 0% (placebo 3.2%) NCT00578305 · Phase 3 · registry result, not featured evidence 1000 mg arthralgia 0% (placebo 1.6%) back pain 0% (placebo 1.6%) bronchitis 0% (placebo 3.2%) NCT00578305 · Phase 3 · registry result, not featured evidence 500 mg arthralgia 6.5% (placebo 1.6%) bronchitis 6.5% (placebo 3.2%) headache 6.5% (placebo 1.6%) NCT00578305 · Phase 3 · registry result, not featured evidence 500 mg arthralgia 0% (placebo 1.6%) back pain 0% (placebo 1.6%) bronchitis 0% (placebo 3.2%) NCT00578305 · Phase 3 · registry result, not featured evidence 500 mg arthralgia 0% (placebo 1.6%) back pain 0% (placebo 1.6%) bronchitis 0% (placebo 3.2%) NCT00578305 · Phase 3 · registry result, not featured evidence Decreased Dose infusion related reaction 36% nasopharyngitis 28% rheumatoid arthritis 28% NCT00422383 · Phase 3 · registry result, not featured evidence · combination Escalated Dose infusion related reaction 37.8% upper respiratory tract infection 31.1% rheumatoid arthritis 27.7% NCT00422383 · Phase 3 · registry result, not featured evidence · combination High Dose infusion related reaction 38.7% rheumatoid arthritis 32.3% upper respiratory tract infection 30.1% NCT00422383 · Phase 3 · registry result, not featured evidence · combination Low Dose infusion related reaction 43.3% rheumatoid arthritis 32.1% upper respiratory tract infection 29.1% NCT00422383 · Phase 3 · registry result, not featured evidence · combination 1000 mg upper respiratory tract infection 12.7% rheumatoid arthritis 12.5% arthralgia 11.7% NCT00443651 · Phase 3 · registry result, not featured evidence 500 mg rheumatoid arthritis 15.9% upper respiratory tract infection 15.3% headache 14.2% NCT00443651 · Phase 3 · registry result, not featured evidence 1000 mg urinary tract infection 17.3% bronchitis 13.6% headache 12.3% NCT01126541 · Phase 3 · registry result, not featured evidence 1000 mg bronchitis 19.7% asthenia 16.7% cough 16.7% NCT01126541 · Phase 3 · registry result, not featured evidence 1000 mg x 2 bronchitis 23.5% rheumatoid arthritis 17.6% urinary tract infection 17.6% NCT01126541 · Phase 3 · registry result, not featured evidence nasopharyngitis 22.3% bronchitis 8.8% upper respiratory tract infection 6.2% NCT00502840 · Phase 3 · registry result, not featured evidence · background therapy infusion reaction 10% NCT00578565 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.3% cough 6.3% hypertension 5.6% NCT02079532 · Phase 3 · registry result, not featured evidence · combination rheumatoid arthritis 16.7% nausea 14.2% headache 11.7% NCT01272908 · Phase 3 · registry result, not featured evidence · combination nausea 11.7% nasopharyngitis 10.4% headache 7.8% NCT01272908 · Phase 3 · registry result, not featured evidence · combination headache 17.2% urinary tract infection 9.9% nausea 9.5% NCT00502996 · Phase 3 · registry result, not featured evidence rheumatoid arthritis 50.8% (placebo 42.5%) infusion related reaction 43.7% (placebo 19.7%) upper respiratory tract infection 32.9% (placebo 5.5%) NCT02093026 · Phase 2 · registry result, not featured evidence rheumatoid arthritis 17.6% headache 13.2% pruritus 13.2% NCT00282308 · Phase 2 · registry result, not featured evidence · combination allergic reaction to detergent on hand and arm 4.2% anemia 4.2% contact dimities 4.2% NCT00147966 · Phase 2 · registry result, not featured evidence 1000 mg upper respiratory tract infection 35% cough 15% insomnia 15% NCT00243412 · Phase 2 · registry result, not featured evidence 500 mg sinusitis 28.6% arthralgia 23.8% nausea 23.8% NCT00243412 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 9.4% bronchitis 3.1% fall 3.1% NCT01643928 · Phase na · registry result, not featured evidence arthralgia 10% asthenia 6.7% back pain 6.7% NCT01643928 · Phase na · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 25 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 48 weeks versus 25 weeks.
- gTrial phases differ: Phase 3 versus Phase na.
- hPopulation comparability has not been reviewed for 12 of these studies.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
PF-05280586
show 6 more results
show 6 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 86 further endpoints in the CSV export.
Rituximab
show 5 more results
show 4 more results
show 1 more result
show 3 more results
+ 288 further endpoints in the CSV export.
Follicular Lymphoma
Shared mechanism: CD20 · full Follicular Lymphoma pipeline
PF-05280586
Marketed by Pfizer
NCT02213263 · Phase 3 · completed
The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.
Reported efficacy
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)
Result source: NCT02213263
Rituximab · Rituxan
Marketed by Roche and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT01479842 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Follicular Lymphoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Rituximab: registry results are on file for Follicular Lymphoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-05280586's landscape · Rituximab's landscape